Login / Signup

Rhabdovirus-based vaccine platforms against henipaviruses.

Drishya KurupChristoph WirblichHeinz FeldmannAndrea MarziMatthias J Schnell
Published in: Journal of virology (2014)
Scientists have been tracking two new viruses carried by the Pteropid fruit bats: Hendra virus (HeV) and Nipah virus (NiV). Both viruses can be fatal to humans and also pose a serious risk to domestic animals. A recent escalation in the frequency of outbreaks has increased the need for a vaccine that prevents HeV and NiV infections. In this study, we performed an extensive comparison of live and killed particles of two recombinant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type or codon-optimized HeV glycoprotein, with the goal of developing a candidate vaccine against HeV. Based on our data from the presented mouse immunogenicity studies, we conclude that a killed RABV vaccine would be highly effective against HeV infections and would make an excellent vaccine candidate in areas where both RABV and henipaviruses pose a threat to human health.
Keyphrases
  • human health
  • wild type
  • risk assessment
  • randomized controlled trial
  • machine learning
  • deep learning
  • study protocol
  • disease virus
  • cell free
  • case control